Drug profile

The FDA adverse-event record for Phytosphingosine Salicyloyl + Pramoxine Hydrochloride

20 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Phytosphingosine Salicyloyl + Pramoxine Hydrochloride. See the species affected, top reactions, and outcomes below.

20
adverse-event reports
5.0%
death-coded share
Dog
most-reported species
4
Pruritus - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
20
Total Reports
1
Deaths Reported
5.0%
Death Rate

Active Ingredients

Phytosphingosine SalicyloylPramoxine Hydrochloride

Administration Routes

TopicalOphthalmic

Species Affected

Dog 16
Human 3
Cat 1

Most Affected Breeds

Unknown 3
Retriever - Golden 3
Retriever - Labrador 2
Dachshund (unspecified) 1
Maltese 1
Spaniel - Cocker American 1
Domestic Shorthair 1
Shepherd Dog - German 1
Brittany 1
Dog (unknown) 1

Most Reported Reactions

Pruritus 4
Erythema (for urticaria see Immune SOC) 3
Glaucoma 3
Hives (see also 'Skin') 2
Application site erythema 2
Application site pruritus 2
Lack of efficacy - NOS 2
Urticaria 2
Accidental exposure 1
Red eye 1
Eye irritation 1
Application site reddening 1

Outcome Breakdown

Recovered/Normal
9 (45.0%)
Ongoing
6 (30.0%)
Outcome Unknown
4 (20.0%)
Euthanized
1 (5.0%)

Phytosphingosine Salicyloyl + Pramoxine Hydrochloride Adverse Event Insights

20 reports name Phytosphingosine Salicyloyl + Pramoxine Hydrochloride; 1 recorded a death outcome (5.0% of reported events, not a population-level mortality rate). Active ingredients: Phytosphingosine Salicyloyl, Pramoxine Hydrochloride. Administration routes: Topical, Ophthalmic.

By species: Dog (16 reports), Human (3 reports), Cat (1 reports). By breed: Unknown (3), Retriever - Golden (3), Retriever - Labrador (2).

Leading clinical signs: Pruritus (4), Erythema (for urticaria see Immune SOC) (3), Glaucoma (3), Hives (see also 'Skin') (2). Outcome, 20 coded reports: Recovered/Normal leads at 45.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.